CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
October 2022—Cofactor Genomics presented initial results from the PREDAPT (Predicting Immunotherapy Efficacy from Analysis of Pre-treatment Tumor Biopsies) multicenter clinical trial at the Advances in Genome Biology and Technology Precision Health Meeting in September. The company says its data show that Cofactor’s OncoPrism test using predictive immune modeling was nearly twice as accurate as PD-L1 assays in determining who will benefit from immunotherapies such as Keytruda (pembrolizumab).
The PREDAPT trial is studying whether a more comprehensive and quantitative profiling of the tumor microenvironment using the OncoPrism assay will lead to a more accurate prediction of responders to immune checkpoint inhibitors for a variety of cancers. The study currently includes 20 health care systems from across the nation, Cofactor says, and will ultimately study 11 solid tumor cancers.